ReviewMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2022

Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations.

Jun Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.